(E)-2-octylidenecyclopentanone | 40564-16-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-2-octylidenecyclopentanone
• 英文别名: 2-octylidenecyclopentanone；2-(E)-octylidene cyclopentanone；(2E)-2-octylidenecyclopentan-1-one
• CAS: 40564-16-7
• 化学式: C₁₃H₂₂O
• 分子量: 194.317
• InChiKey: WWHQKPBWGGRGPU-FMIVXFBMSA-N

物化性质

• 沸点：
  165 °C(Press: 10 Torr)
• 密度：
  0.964±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-2-octylidenecyclopentanone 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以100%的产率得到(+/-)-(E)-2-Octylidenecyclopentan-1-ol
  参考文献：
  名称：

  Asymmetric reduction of prochiral cycloalkenones. The influence of exocyclic alkene geometry

  摘要：

  本研究介绍了使用科里噁唑硼烷 2 对一系列具有一般结构 1 的手性烯酮进行不对称还原，从而得到对映体富集的烯丙基环烷醇 3 的过程。在分别基于环己酮和环戊酮的 (E)- 和 (Z)-4 和 (E)- 和 (Z)-7 两个系统中，探究了烯烃几何形状对不对称还原过程的意义 (Rvs. S) 和效率 (% ee) 的影响。通过对氨基甲酸酯 10 进行 X 射线晶体分析，确定了环戊基衍生物 (E)-8 的绝对立体化学结构。根据 Riguera 早先描述的核磁共振方法，对分配烯丙基醇 3 绝对构型的能力进行了评估。

  DOI：

  10.1039/b004540n
• 作为产物：
  描述：

  正辛醛 、 环戊酮 在 (S)-N-(2,2,2-trifluoroacetyl)pyrrolidine-2-carboxamide 作用下， 以 二甲基亚砜 为溶剂， 反应 47.0h， 以59%的产率得到(E)-2-octylidenecyclopentanone
  参考文献：
  名称：

  一种新型的吡咯烷酰亚胺催化未改性的酮和醛直接形成α，β-不饱和酮。

  摘要：

  由酮和醛直接，立体选择性地制备（E）-α，β-不饱和酮的方法，由新型吡咯烷酰亚胺有机催化剂促进，已经以中等至高收率开发。与Claisen-Schmidt缩合反应和Lewis酸催化的串联醛醇缩合脱水过程不同，此方法提供了温和的反应条件，可从简单的未改性酮中获得α，β-不饱和酮。[反应：看文字]

  DOI：

  10.1021/ol047630g

文献信息

• [EN] ORGANOCATALYSTS AND METHODS OF USE IN CHEMICAL SYNTHESIS<br/>[FR] ORGANOCATALYSEURS ET PROCEDES D'UTILISATION DE CES DERNIERS DANS LA SYNTHESE CHIMIQUE
  申请人：STC UNM

  公开号：WO2006007586A1

  公开（公告）日：2006-01-19

  The present invention pertains generally to compositions comprising organocatalysts that facilitate stereo-selective reactions and the method of their synthesis and use. Particularly, the invention relates to metal-free organocatalysts for facilitation of stereo-­selective reactions, and the method of their synthesis and use. These compounds have the structure of the Formulas (I) and (II). Where X is independently selected from CH2, N-Ra, O, S or C=O; Y is CH2, N-Ra, O, S or C=O, with the proviso that at least one of X or Y is CH2, and preferably both of X and Y are CH2; Ra is H, an optionally substituted C1-C12 alkyl, preferably an optionally substituted C1-C6 alkyl including a C3-C6 cyclic alkyl group, or an optionally substituted aryl group, preferably an optionally substituted phenyl group; Rb is H, an optionally substituted C1-C12 alkyl, preferably an optionally substituted C1-C6 acyclic or a a C3-C6 cyclic alkyl group, CHO, N(Me)O, CO(S)Ra or the group of Formula (III). Where Rc and Rd are each independently H, F, C1, an optionally substituted C1-C20 alkyl, preferably an optionally substituted C1-C12 alkyl, more preferably a C1-C6 alkyl, and an optionally substituted aryl group, or together Rc and Rd form an optionally substituted carbocyclic or optionally substituted heterocyclic ring; R1 is OH, OR, NR'R', NHC(=O)R, NHSO2R; R2 is H, F, C1, an optionally substituted C1-C20 alkyl, preferably an optionally substituted C1­C6 alkyl, an optionally substituted aryl group or a =O group (which establishes a carbonyl group with the carbon to which =O is attached; R3 is H, OH, F, C1, Br, I, Cl, an optionally substituted C1-C20 alkyl, alkenyl or alkynyl ('hydrocarbyl') group, preferably an optionally substituted C1-C6 alkyl, or an optionally substituted aryl, such that the carbon to which R3 is attached has an R or S configuration; R is H, an optionally substituted C1-C20 alkyl, preferably an optionally substituted C1-C6 alkyl, or an optionally substituted aryl group, R' and R' are each independently H, an optionally substituted C1-C20 alkyl group, preferably an optionally substituted C1-C6 alkyl, or an optionally substituted aryl group; or together R' and R' form an optionally substituted heterocyclic, preferably a 4 to 7 membered optionally substituted heterocyclic group or an optionally substituted heteroaryl ring with the nitrogen to which R' and R' are attached; and wherein said compound is free from a metal catalyst.

  本发明涉及一般包括有机催化剂的组合物，该催化剂促进立体选择性反应以及其合成和使用方法。特别地，本发明涉及无金属有机催化剂以促进立体选择性反应，以及其合成和使用方法。这些化合物具有以下结构的式（I）和（II）。其中X独立地选择自CH2、N-Ra、O、S或C=O；Y为CH2、N-Ra、O、S或C=O，但至少X或Y中的一个为CH2，最好是X和Y都为CH2；Ra为H、可选择地取代的C1-C12烷基，最好是可选择地取代的C1-C6烷基，包括C3-C6环烷基，或可选择地取代的芳基，最好是可选择地取代的苯基；Rb为H、可选择地取代的C1-C12烷基，最好是可选择地取代的C1-C6无环或C3-C6环烷基，CHO、N(Me)O、CO(S)Ra或式（III）的基团。其中Rc和Rd各自独立地为H、F、C1、可选择地取代的C1-C20烷基，最好是可选择地取代的C1-C12烷基，更好地是C1-C6烷基，以及可选择地取代的芳基，或者Rc和Rd一起形成可选择地取代的碳环或可选择地取代的杂环；R1为OH、OR、NR'R'、NHC(=O)R、NHSO2R；R2为H、F、C1、可选择地取代的C1-C20烷基，最好是可选择地取代的C1-C6烷基，可选择地取代的芳基或=O基团（与=O连接的碳形成羰基基团）；R3为H、OH、F、C1、Br、I、Cl、可选择地取代的C1-C20烷基、烯基或炔基（'烃基'），最好是可选择地取代的C1-C6烷基，或可选择地取代的芳基，使得R3连接的碳具有R或S构型；R为H、可选择地取代的C1-C20烷基，最好是可选择地取代的C1-C6烷基，或可选择地取代的芳基，R'和R'各自独立地为H、可选择地取代的C1-C20烷基，最好是可选择地取代的C1-C6烷基，或可选择地取代的芳基；或者R'和R'一起形成可选择地取代的杂环，最好是4到7成员的可选择地取代的杂环基团或与R'和R'连接的氮原子形成可选择地取代的杂芳基环；其中所述化合物不含金属催化剂。
• Process for producing 2-alkyl-2cyclopentenones
  申请人：TAKASAGO INTERNATIONAL CORPORATION

  公开号：US20030109755A1

  公开（公告）日：2003-06-12

  Industrially advantageous processes for producing a 2-alkyl-2-cyclopentenone in high yields starting from a 2-(1-hydroxyalkyl)cyclopentanone or a 2-alkylidenecyclopentanone, which are obtainable from a cyclopentanone and a carbonyl compound. A 2-(1-hydroxyalkyl)cyclopentanone represented by the following general formula (1): 1 (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents hydrogen atom, an alkyl group having 1 to 10 carbon atoms which may have one or more substituents or an aromatic group which may have one or more substituents, and each of (1) R 6 or R 7 with R 3 and (2) R 6 or R 7 with R 4 or R 5 may be together combined to form a ring which may have a double bond) is subjected to dehydrative isomerization in the presence of a bromine compound and/or an iodine compound.

  从环戊酮和羰基化合物获得的2-(1-羟基烷基)环戊酮或2-烷基亚烯环戊酮，是从高产率开始生产2-烷基-2-环戊酮的工业上有利的过程。在以下一般式（1）中表示的2-(1-羟基烷基)环戊酮中（其中R1、R2、R3、R4、R5、R6和R7分别独立地表示氢原子、具有1至10个碳原子的烷基基团，可能具有一个或多个取代基或可能具有一个或多个取代基的芳香基团，且(1) R6或R7与R3和(2) R6或R7与R4或R5中的每一个可能结合在一起形成可能具有双键的环)在溴化合物和/或碘化合物的存在下进行脱水异构化。
• PROSTAGLANDIN ANALOGS AND USES THEREOF
  申请人：Lifex Biolabs, Inc.

  公开号：US20210139435A1

  公开（公告）日：2021-05-13

  The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.

  本发明涉及一种药物组合物，用于预防或治疗与Nurr1相关的疾病、紊乱或状况，其中包括作为活性成分的前列腺素类似物或其药学上可接受的盐，该化合物具有良好的诱导Nurr1的效果，因此，可用作预防或治疗与Nurr1相关的疾病、紊乱或状况的药物组合物，特别是癌症、自身免疫性疾病如类风湿关节炎、精神分裂症、躁郁症以及神经退行性疾病如阿尔茨海默病或帕金森病。
• 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones,
  申请人：University of Pittsburgh

  公开号：US05250735A1

  公开（公告）日：1993-10-05

  Novel 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof having the formula ##STR1## wherein x is methylene or ethylene; R.sub.1 is dimethylamino, diethylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, anilino or substituted anilino; R.sub.2 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; R.sub.3 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; and R.sub.4 is hydrogen, methyl, ethyl, allyl, benzyl, substituted benzyl, cyclopentyl, substituted cyclopentyl, cyclopenten-1-yl, or substituted cyclopenten-1-yl; and wherein aryl is phenyl or phenyl substituted with one or more methoxyl, hydroxyl, methylenedioxy, chloro, bromo, fluoro, ethoxycarbonylmethoxy, benzoxy, alkyl group, or their combination, possess anti-inflammatory, analgesic and anticancer properties. The methods of using these compounds to treat inflammation, pain and cancer in mammals and to resist or substantially prevent inflammation and pain in mammals are also disclosed.

  2-(N-取代氨基烷基)-5-(E)-取代芳基烷基亚甲基环戊酮，2-(N-取代氨基烷基)-5-(E)-芳基烷基亚甲基环戊酮及其衍生物，其化学式为：##STR1## 其中x为亚甲基或乙烯基；R.sub.1为二甲氨基，二乙氨基，1-吡咯烷基，1-哌啶基，4-吗啉基，苯胺基或取代苯胺基；R.sub.2为氢，直链或支链烷基，长度为1到9个碳原子，芳基或芳基烷基；R.sub.3为氢，直链或支链烷基，长度为1到9个碳原子，芳基或芳基烷基；R.sub.4为氢，甲基，乙基，烯丙基，苄基，取代苄基，环戊基，取代环戊基，环戊-1-烯基或取代环戊-1-烯基；其中芳基为苯基或经过一个或多个甲氧基，羟基，亚甲基二氧基，氯，溴，氟，乙氧羰基甲氧基，苯氧基，烷基或其组合取代的苯基。这些化合物具有抗炎，镇痛和抗癌特性。本文还公开了使用这些化合物治疗哺乳动物的炎症，疼痛和癌症以及抵抗或显著预防哺乳动物炎症和疼痛的方法。
• Method of treating inflammation and pain with
  申请人：University of Pittsburgh of the Commonwealth System of Higher Education

  公开号：US05281622A1

  公开（公告）日：1994-01-25

  Novel 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof having the formula ##STR1## wherein x is methylene or ethylene; R.sub.1 is dimethylamino, diethylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, anilino or substituted anilino; R.sub.2 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; R.sub.3 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; and R.sub.4 is hydrogen, methyl, ethyl, allyl, benzyl, substituted benzyl, cyclopentyl, substituted cyclopentyl, cyclopenten-1-yl, or substituted cyclopenten-1-yl; and wherein aryl is phenyl or phenyl substituted with one or more methoxyl, hydroxyl, methylenedioxy, chloro, bromo, fluoro, ethoxycarbonylmethoxy, benzoxy, alkyl group, or their combination, possess anti-inflammatory, analgesic and anticancer properties. The methods of using these compounds to treat inflammation, pain and cancer in mammals and to resist or substantially prevent inflammation and pain in mammals are also disclosed.

  第二类小说-2-(N-取代氨基烷基)-5-(E)-取代烷基环戊酮，2-(N-取代氨基烷基)-5-(E)-芳基烷基环戊酮及其衍生物，其化学式为##STR1## 其中x为亚甲基或乙烯基; R.sub.1为二甲氨基，二乙氨基，1-吡咯啉基，1-哌啶基，4-吗啉基，苯胺基或取代苯胺基; R.sub.2为氢，1至9个碳原子的直链或支链烷基，芳基或芳基烷基; R.sub.3为氢，1至9个碳原子的直链或支链烷基，芳基或芳基烷基; R.sub.4为氢，甲基，乙基，烯丙基，苄基，取代苄基，环戊基，取代环戊基，环戊烯-1-基或取代环戊烯-1-基; 其中芳基为苯基或取代苯基，取代基包括一个或多个甲氧基，羟基，亚甲基二氧基，氯，溴，氟，乙氧羰甲氧基，苯氧基，烷基或它们的组合，具有抗炎，镇痛和抗癌特性。还公开了使用这些化合物治疗哺乳动物的炎症，疼痛和癌症，并抵抗或显著预防哺乳动物的炎症和疼痛的方法。